Biora Therapeutics, Inc. (BIOR)

Market Cap	2.08M
Revenue (ttm)	892.00K
Net Income (ttm)	-31.54M
Shares Out	4.42M
EPS (ttm)	-10.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,700
Open	0.493
Previous Close	0.531
Day's Range	0.440 - 0.493
52-Week Range	0.260 - 19.900
Beta	1.12
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 27, 2025

About Biora Therapeutics

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 58
• Stock Exchange: OTCMKTS
• Ticker Symbol: BIOR

Financial Performance

In 2023, Biora Therapeutics's revenue was $4,000, a decrease of -98.69% compared to the previous year's $305,000. Losses were -$124.12 million, 225.3% more than in 2022.